Press Releases

More than two dozen Roswell Park physicians and researchers will be take part in the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago June 3–7, presenting research findings, leading sessions and connecting with colleagues from around the world.

An immune-based therapy developed at Roswell Park Cancer Institute (RPCI) is moving forward with its third clinical trial. The early-stage clinical trial will assess whether SurVaxM — a cancer vaccine developed at Roswell Park — is a safe and effective treatment option for patients with multiple myeloma, a rare type of blood cancer.

Researchers in the Center for Immunotherapy at Roswell Park Cancer Institute (RPCI) have evaluated the human leukocyte antigen (HLA), a group of genes that help regulate the body’s immune system, for underlying differences in ovarian cancer patients’ response to therapy. The

Only 12% of kidney cancer patients with advanced disease survive five years after their initial treatment. In a Roswell Park Cancer Institute-led study, scientists report that some patients with advanced kidney cancer who continued to receive a novel immunotherapy drug after their disease progressed saw clinical benefit.

Everyone’s life is a story — a tale of challenges and triumphs, perseverance, hope and love. If you are a cancer survivor, you are invited to share your story and listen as others tell theirs during a special event Saturday, June 4, from 8:15 a.m. to 3 p.m. at Roswell Park Cancer Institute. The event, “A Hero’s Journey,” will explore the power of storytelling in the healing process.

Roswell Park Comprehensive Cancer Center ushered in a new chapter today with the opening of the Scott Bieler Clinical Sciences Center on its main campus. The 11-story, 142,000-square-foot facility adjacent to and accessible from the Roswell Park main hospital will be dedicated to targeted clinical programs and support services.

Even 30 minutes of exercise per week has the potential to significantly reduce a woman’s risk of developing cervical cancer, according to a study from scientists at Roswell Park Cancer Institute. The case-control study was recently published in the Journal of Lower Genital Tract Disease.

Adoptive T cell therapy has emerged as a promising treatment for patients with metastatic melanoma. But efforts to apply these advances clinically have been limited by difficulties in obtaining long-lasting T cells that can survive following infusion. A team of researchers from Roswell Park Cancer Institute, the University of Michigan and Kyoto University has reported significant progress in this area, achieving the first successful generation of pluripotent stem cells from melanoma-targeting T cells in a preclinical study.

Alan Hutson, PhD, Chair of the Department of Biostatistics & Bioinformatics and Associate Director of the Biostatistics Shared Resource at Roswell Park, has been named a scientific merit reviewer for the Improving Healthcare Systems Program of the Patient-Centered Outcomes Research Institute, an independent nonprofit organization.